SCHEMBL434613

SCHEMBL434613

Nc1ccc(C(F)(F)F)nc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.40
ALDH1A1 P00352 4/20 0.40
HSD17B10 Q99714 2/20 0.40
MAT2A P31153 1/20 0.36
HSP90AA1 P07900 1/20 0.35
HSP90AB1 P08238 1/20 0.35
TRPV4 Q9HBA0 1/20 0.34
FFAR1 O14842 1/20 0.34
FFAR4 Q5NUL3 1/20 0.34
CA2 P00918 2/20 0.33
P2RX7 Q99572 1/20 0.33
CHKA P35790 1/20 0.33
KMT2A Q03164 1/20 0.33
NT5E P21589 1/20 0.33
PTGS2 P35354 2/20 0.33
ADORA2A P29274 1/20 0.32
ADORA1 P30542 1/20 0.32
PIK3CD O00329 1/20 0.32
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29626668 1.00 KDM4E (0.40) KDM4EALDH1A1HSD17B10MAT2AHSP90AA1
SCHEMBL12072127 0.78 HSD17B2 (0.34) KDM4EALDH1A1HSD17B10CA2CA12
SCHEMBL4371685 0.77 NT5E (0.39) KDM4EALDH1A1HSD17B10MAT2ATRPV4
SCHEMBL29745069 0.77 HSP90AA1 (0.38) KDM4EALDH1A1HSD17B10MAT2AHSP90AA1
SCHEMBL898882 0.77 HSP90AA1 (0.38) KDM4EALDH1A1HSD17B10MAT2AHSP90AA1
SCHEMBL23319536 0.76 ALDH1A1 (0.43) KDM4EALDH1A1HSD17B10MAT2AKMT2A
SCHEMBL830696 0.76 HSP90AA1 (0.36) KDM4EALDH1A1HSD17B10MAT2AHSP90AA1
SCHEMBL25371113 0.76 HSP90AA1 (0.36) KDM4EALDH1A1HSD17B10MAT2AHSP90AA1
Hydrochloric Acid SCHEMBL14127591 0.76 HSP90AA1 (0.36) KDM4EALDH1A1HSD17B10MAT2AHSP90AA1
SCHEMBL23162813 0.76 KDM4E (0.37) KDM4EALDH1A1HSD17B10MAT2ATRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101959863-B Process for production of 3-amino-2-chloro-6- trifluoromethylpyridine ISHIHARA SANGYO KAISHA 2014-01-08 CN claimed
EP-2251329-A1 PROCESS FOR PRODUCTION OF 3-AMINO-2-CHLORO-6- TRIFLUOROMETHYLPYRIDINE ISHIHARA SANGYO KAISHA, LTD. (JP) 2010-11-17 EP claimed
US-20250361237-A1 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE ORIGENIS GMBH (DE) 2025-11-27 US disclosed
US-20250346600-A1 TRICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. 2025-11-13 US disclosed
EP-4601746-A1 TRICYCLIC COMPOUNDS AND THEIR USES Novartis AG (CH) 2025-08-20 EP disclosed
US-12384788-B2 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as LRRK2, NUAK1 and/or TYK2 kinase modulators for the treatment of e.g. autoimmune disease ORIGENIS GMBH (DE) 2025-08-12 US disclosed
US-20250230168-A1 AZASPIRO WRN INHIBITORS GILEAD SCIENCES, INC. 2025-07-17 US disclosed
EP-4583870-A2 MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER Mito Biopharma, LLC (US) 2025-07-16 EP disclosed
WO-2025137640-A1 AZASPIRO WRN INHIBITORS GILEAD SCIENCES, INC. (US) 2025-06-26 WO disclosed
EP-4562009-A1 NOVEL COMPOUNDS AC Immune SA (CH) 2025-06-04 EP disclosed
US-20250163043-A1 CDK9 INHIBITOR AND USE THEREOF TRANSTHERA SCIENCES (NANJING), INC. (CN) 2025-05-22 US disclosed
EP-1551811-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS Amgen Inc. (US) 2005-07-13 EP disclosed
US-20050054661-A1 Corticotropin releasing factor antagonists GLAXO GROUP LIMITED (GB) 2005-03-10 US disclosed
US-20040152690-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2004-08-05 US disclosed
WO-2004035549-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS AMGEN INC. (US) 2004-04-29 WO disclosed
EP-1395591-A1 CORTICOTROPIN RELEASING FACTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2004-03-10 EP disclosed
WO-2002100863-A1 CORTICOTROPIN RELEASING FACTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2002-12-19 WO disclosed
US-6225320-B1 TREATMENT OF PAIN, INFLAMMATION, MIGRAINE, EMESIS AND POSTTHERPETIC NEURALGIA MERCK SHARP & DOHME LTD. (GB) 2001-05-01 US disclosed
EP-0989987-A1 SPIRO-AZACYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LTD. (GB) 2000-04-05 EP disclosed
WO-1998054187-A1 SPIRO-AZACYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LIMITED (GB) 1998-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250230168-A1 AZASPIRO WRN INHIBITORS WRN, RECQL, BLM KDM4E 3650/4885ALDH1A1 1316/4885HSD17B10 2216/4885
US-12384788-B2 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as LRRK2, NUAK1 and/or TYK2 kinase modulators for the treatment of e.g. autoimmune disease NUAK1, TYK2, MARK1 KDM4E 1496/4885ALDH1A1 2169/4885HSD17B10 3954/4885
US-20050054661-A1 Corticotropin releasing factor antagonists CRHR1, CRH, CRHR2 KDM4E 3877/4885ALDH1A1 4396/4885HSD17B10 940/4885
US-20040152690-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV3, TRPV2 KDM4E 3639/4885ALDH1A1 2522/4885HSD17B10 3754/4885
US-20250361237-A1 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE NUAK1, TYK2, MARK1 KDM4E 1496/4885ALDH1A1 2169/4885HSD17B10 3954/4885
US-20250163043-A1 CDK9 INHIBITOR AND USE THEREOF CDK9, CDK19, CDKL1 KDM4E 510/4885ALDH1A1 2791/4885HSD17B10 3785/4885
US-20250346600-A1 TRICYCLIC DERIVATIVES AND RELATED USES WRN, RECQL, BLM KDM4E 3487/4885ALDH1A1 1509/4885HSD17B10 1735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.